RO5256390

RO-5256390
Identifiers
	IUPAC name (S)-4-((S)-2-phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine;
CAS Number	1043495-96-0;
PubChem CID	24963286;
ChemSpider	34959936;
ChEMBL	ChEMBL3684869;
Chemical and physical data
Formula	C13H18N2O
Molar mass	218.300 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC1=N[C@@H](C[C@@H](C2=CC=CC=C2)CC)CO1;
	InChI InChI=1S/C13H18N2O/c1-2-10(11-6-4-3-5-7-11)8-12-9-16-13(14)15-12/h3-7,10,12H,2,8-9H2,1H3,(H2,14,15)/t10-,12-/m0/s1; Key:IXDKFUBXESWHSL-JQWIXIFHSA-N;

RO5256390 or RO-5256390 is a drug developed by Hoffmann-La Roche which acts as an agonist for the trace amine associated receptor 1 (TAAR1), which has been shown to block compulsive and binge-like eating behavior in rats. For this reason, it is being investigated as a potential drug to treat binge eating disorder.^[1] The drug shows robust aversive and locomotor-suppressing effects in rodents that are dependent on TAAR1 activation.^[2] Similar aversive effects have also been observed with other TAAR1 agonists like RO5263397 and RO5166017.^[2]^[3]

RO5256390 at TAAR1 in different species^[4]
Species	Affinity (K_i, nM)	EC₅₀Tooltip half-maximal effective concentration (nM)	E_maxTooltip maximal efficacy (%)
Mouse	4.4	2–18	68–79%
Rat	2.9	5.1	107%
Monkey	16	16	100%
Human	24	16	98%

Reference section

^ Ferragud A, Howell AD, Moore CF, Ta TL, Hoener MC, Sabino V, Cottone P (June 2017). "The Trace Amine-Associated Receptor 1 Agonist RO5256390 Blocks Compulsive, Binge-like Eating in Rats". Neuropsychopharmacology. 42 (7): 1458–1470. doi:10.1038/npp.2016.233. PMC 5436108. PMID 27711047.
^ ^a ^b Shabani S, Houlton S, Ghimire B, Tonello D, Reed C, Baba H, Aldrich S, Phillips TJ (September 2023). "Robust aversive effects of trace amine-associated receptor 1 activation in mice". Neuropsychopharmacology. 48 (10): 1446–1454. doi:10.1038/s41386-023-01578-4. PMC 10425385. PMID 37055488.
^ Liu J, Wu R, Johnson B, Zhang Y, Zhu Q, Li JX (October 2022). "Selective TAAR1 agonists induce conditioned taste aversion". Psychopharmacology (Berl). 239 (10): 3345–3353. doi:10.1007/s00213-022-06222-5. PMID 36056214.
^ Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, Metzler V, Chaboz S, Groebke Zbinden K, Galley G, Norcross RD, Tuerck D, Bruns A, Morairty SR, Kilduff TS, Wallace TL, Risterucci C, Wettstein JG, Hoener MC (May 2013). "A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight". Mol Psychiatry. 18 (5): 543–556. doi:10.1038/mp.2012.57. PMID 22641180.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.